Molecular targets in metastasis: Lessons from genomic approaches

Cancer Genomics and Proteomics

Volumn 4, Issue 3, 2007, Pages 211-222

  Fingleton, Barbara ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Collagen; CSF 1; CXCR4; Host; Microarray; Osteopontin; Profile; Review; rhoC

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); CHEMOKINE RECEPTOR CXCR4; COLLAGEN TYPE 1; COLONY STIMULATING FACTOR 1; OSTEOPONTIN; PROTEIN RHOC; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG;

CANCER GROWTH; DRUG TARGETING; GENE FUNCTION; GENE MUTATION; GENOME; GENOMICS; GENOTYPE; HOST; HUMAN; MEDICAL DECISION MAKING; MEDICAL INFORMATION; METASTASIS; MICROARRAY ANALYSIS; MOLECULAR BIOLOGY; NONHUMAN; PREDICTION; PROGNOSIS; PROTEIN SYNTHESIS; REVIEW; TREATMENT PLANNING; TUMOR CELL;

EID: 34249333868     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Review

References (108)

1. Hynes RO: Metastatic potential: generic predisposition of the primary tumor or rare, metastatic variants-or both? Cell 113: 821-823, 2003.
2. Bernards R and Weinberg RA: A progression puzzle. Nature 418: 823, 2002.
3. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH and Bernards R: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009, 2002.
4. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R and Friend SH: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536, 2002.
5. Weigelt B, Hu Z, He X, Livasy C, Carey LA, Ewend MG, Glas AM, Perou CM and Van't Veer LJ: Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res 65: 9155-9158, 2005.
6. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO and Botstein D: Molecular portraits of human breast tumours. Nature 406: 747-752, 2000.
7. Ramaswamy S, Ross KN, Lander ES and Golub TR: A molecular signature of metastasis in primary solid tumors. Nat Genet 33: 49-54, 2003.
8. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C, Guise TA and Massague J: A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3: 537-549, 2003.
9. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL and Massague J: Genes that mediate breast cancer metastasis to lung. Nature 436: 518-524, 2005.
10. Minn AJ, Kang Y, Serganova I, Gupta GP, Giri DD, Doubrovin M, Ponomarev V, Gerald WL, Blasberg R and Massague J: Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest 115: 44-55, 2005.
11. Fidler IJ: The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 3: 453-458, 2003.
12. Hunter KW, Crawford NP: Germ line polymorphism in metastatic progression. Cancer Res 66: 1251-1254, 2006.
13. Guy CT, Cardiff RD and Muller WJ: Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Molec Cell Biol 12: 954-961, 1992.
14. Lifsted T, Le Voyer T, Williams M, Muller W, Klein-Szanto A, Buetow KH and Hunter KW: Identification of inbred mouse strains harboring genetic modifiers of mammary tumor age of onset and metastatic progression. Int J Cancer 77: 640-644, 1998.
15. Lancaster M, Rouse J and Hunter KW: Modifiers of mammary tumor progression and metastasis on mouse chromosomes 7, 9, and 17. Mamm Genome 16: 120-126, 2005.
16. Park YG, Zhao X, Lesueur F, Lowy DR, Lancaster M, Pharoah P, Qian X and Hunter KW: Sipa1 is a candidate for underlying the metastasis efficiency modifier locus Mtes1. Nat Genet 37: 1055-1062, 2005.
17. Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ and Pollard JW: Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol 163: 2113-2126, 2003.
18. Desai KV, Xiao N, Wang W, Gangi L, Greene J, Powell JI, Dickson R, Furth P, Hunter K, Kucherlapati R, Simon R, Liu ET and Green JE: Initiating oncogenic event determines gene-expression patterns of human breast cancer models. Proc Natl Acad Sci USA 99: 10227-10231, 2002.
19. Qiu TH, Chandramouli GV, Hunter KW, Alkharouf NW, Green JE and Liu ET: Global expression profiling identifies signatures of tumor virulence in MMTV-PyMT-transgenic mice: correlation to human disease. Cancer Res 64: 5973-5981, 2004.
20. Crawford NP, Ziogas A, Peel DJ, Hess J, Anton-Culver H and Hunter KW: Germline polymorphisms in SIPA1 are associated with metastasis and other indicators of poor prognosis in breast cancer. Breast Cancer Res 8: R16, 2006.
21. Yang H, Crawford N, Lukes L, Finney R, Lancaster M and Hunter KW: Metastasis predictive signature profiles pre-exist in normal tissues. Clin Exp Metastasis 22: 593-603, 2005.
22. McKillop IH, Moran DM, Jin X and Koniaris LG: Molecular pathogenesis of hepatocellular carcinoma. J Surg Res 136: 125-135, 2006.
23. American Cancer Society. What are the key statistics about liver cancer? http: //www.cancer.org/docroot/CRI/content/ CRI_2_4_1X_What_are_the_key_statistics_for_liver_cancer_25.asp?sitearea=. Accessed 1.12.07.
24. Budhu AS, Zipser B, Forgues M, Ye QH, Sun Z and Wang XW: The molecular signature of metastases of human hepatocellular carcinoma. Oncology 69(Suppl 1): 23-27, 2005.
25. Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, Simon R, Li Y, Robles AI, Chen Y, Ma ZC, Wu ZQ, Ye SL, Liu YK, Tang ZY and Wang XW: Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 9: 416-423, 2003.
26. Budhu A, Forgues M, Ye QH, Jia HL, He P, Zanetti KA, Kammula US, Chen Y, Qin LX, Tang ZY and Wang XW: Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 10: 99-111, 2006.
27. Clark EA, Golub TR, Lander ES and Hynes RO: Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406: 532-535, 2000.
28. Ridley AJ: The GTP-binding protein Rho. Int J Biochem Cell Biol 29: 1225-1229, 1997.
29. Kleer CG, Teknos TN, Islam M, Marcus B, Lee JS, Pan Q and Merajver SD: RhoC GTPase expression as a potential marker of lymph node metastasis in squamous cell carcinomas of the head and neck. Clin Cancer Res 12: 4485-4490, 2006.
30. Faried A, Faried LS, Kimura H, Nakajima M, Sohda M, Miyazaki T, Kato H, Usman N and Kuwano H: RhoA and RhoC proteins promote both cell proliferation and cell invasion of human oesophageal squamous cell carcinoma cell lines in vitro and in vivo. Eur J Cancer 42: 1455-1465, 2006.
31. Kusama T, Mukai M, Endo H, Ishikawa O, Tatsuta M, Nakamura H and Inoue M: Inactivation of Rho GTPases by p190 RhoGAP reduces human pancreatic cancer cell invasion and metastasis. Cancer Sci 97: 848-853, 2006.
32. Yao H, Dashner EJ, van Golen CM and van Golen KL: RhoC GTPase is required for PC-3 prostate cancer cell invasion but not motility. Oncogene 25: 2285-2296, 2006.
33. Pille JY, Denoyelle C, Varet J, Bertrand JR, Soria J, Opolon P, Lu H, Pritchard LL, Vannier JP, Malvy C, Soria C and Li H: Anti-RhoA and anti-RhoC siRNAs inhibit the proliferation and invasiveness of MDA-MB-231 breast cancer cells in vitro and in vivo. Mol Ther 11: 267-274, 2005.
34. Simpson KJ, Dugan AS and Mercurio AM: Functional analysis of the contribution of RhoA and RhoC GTPases to invasive breast carcinoma. Cancer Res 64: 8694-8701, 2004.
35. Wang W, Yang LY, Huang GW, Lu WQ, Yang ZL, Yang JQ and Liu HL: Genomic analysis reveals RhoC as a potential marker in hepatocellular carcinoma with poor prognosis. Br J Cancer 90: 2349-2355, 2004.
36. Bellovin DI, Simpson KJ, Danilov T, Maynard E, Rimm DL, Oettgen P and Mercurio AM: Reciprocal regulation of RhoA and RhoC characterizes the EMT and identifies RhoC as a prognostic marker of colon carcinoma. Oncogene 25: 6959-6967, 2006.
37. Kleer CG, Griffith KA, Sabel MS, Gallagher G, van Golen KL, Wu ZF and Merajver SD: RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast. Breast Cancer Res Treat 93: 101-110, 2005.
38. Ruth MC, Xu Y, Maxwell IH, Ahn NG, Norris DA and Shellman YG: RhoC promotes human melanoma invasion in a PI3K/Akt-dependent pathway. J Invest Dermatol 126: 862-868, 2006.
39. Hakem A, Sanchez-Sweatman O, You-Ten A, Duncan G, Wakeham A, Khokha R and Mak TW: RhoC is dispensable for embryogenesis and tumor initiation but essential for metastasis. Genes Dev 19: 1974-1979, 2005.
40. Denhardt DT and Guo X: Osteopontin: a protein with diverse functions. FASEB J 7: 1475-1482, 1993.
41. Oates AJ, Barraclough R and Rudland PS: The role of osteopontin in tumorigenesis and metastasis. Invasion Metastasis 17: 1-15, 1997.
42. Al-Shami R, Sorensen ES, Ek-Rylander B, Andersson G, Carson DD and Farach-Carson MC: Phosphorylated osteopontin promotes migration of human choriocarcinoma cells via a p70 S6 kinase-dependent pathway. J Cell Biochem 94: 1218-1233, 2005.
43. Das R, Mahabeleshwar GH and Kundu GC: Osteopontin induces AP-1-mediated secretion of urokinase-type plasminogen activator through c-Src-dependent epidermal growth factor receptor transactivation in breast cancer cells. J Biol Chem 279: 11051-11064, 2004.
44. Tuck AB, Hota C, Wilson SM and Chambers AF: Osteopontin-induced migration of human mammary epithelial cells involves activation of EGF receptor and multiple signal transduction pathways. Oncogene 22: 1198-1205, 2003.
45. El-Tanani MK, Campbell FC, Kurisetty V, Jin D, McCann M and Rudland PS: The regulation and role of osteopontin in malignant transformation and cancer. Cytokine Growth Factor Rev 17: 463-474, 2006.
46. Jain S, Chakraborty G, Bulbule A, Kaur R and Kundu GC: Osteopontin: an emerging therapeutic target for anticancer therapy. Expert Opin Ther Targets 11: 81-90, 2007.
47. Rittling SR and Chambers AF: Role of osteopontin in tumour progression. Br J Cancer 90: 1877-1881, 2004.
48. Ramankulov A, Lein M, Kristiansen G, Loening SA and Jung K: Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer. Prostate 67: 330-340, 2007.
49. Matsuzaki H, Shima K, Muramatsu T, Ro Y, Hashimoto S, Shibahara T and Shimono M: Osteopontin as biomarker in early invasion by squamous cell carcinoma in tongue. J Oral Pathol Med 36: 30-34, 2007.
50. Ito T, Hashimoto Y, Tanaka E, Kan T, Tsunoda S, Sato F, Higashiyama M, Okumura T and Shimada Y: An inducible short-hairpin RNA vector against osteopontin reduces metastatic potential of human esophageal squamous cell carcinoma in vitro and in vivo. Clin Cancer Res 12: 1308-1316, 2006.
51. Matusan K, Dordevic G, Stipic D, Mozetic V and Lucin K: Osteopontin expression correlates with prognostic variables and survival in clear cell renal cell carcinoma. J Surg Oncol 94: 325-331, 2006.
52. Sakaguchi H, Fujimoto J, Hong BL and Tamaya T: Clinical implications of osteopontin in metastatic lesions of uterine cervical cancers. Cancer Lett 247: 98-102, 2007.
53. Kadkol SS, Lin AY, Barak V, Kalickman I, Leach L, Valyi-Nagy K, Majumdar D, Setty S, Maniotis AJ, Folberg R and Pe'er J: Osteopontin expression and serum levels in metastatic uveal melanoma: a pilot study. Invest Ophthalmol Vis Sci 47: 802-806, 2006.
54. Bramwell VH, Doig GS, Tuck AB, Wilson SM, Tonkin KS, Tomiak A, Perera F, Vandenberg TA and Chambers AF: Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin Cancer Res 12: 3337-3343, 2006.
55. Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, Cantor A, Coppola D and Yeatman TJ: Osteopontin identified as colon cancer tumor progression marker. C R Biol 326: 1041-1043, 2003.
56. Pan HW, Ou YH, Peng SY, Liu SH, Lai PL, Lee PH, Sheu JC, Chen CL and Hsu HC: Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer 98: 119-127, 2003.
57. Xie H, Song J, Du R, Liu K, Wang J, Tang H, Bai F, Liang J, Lin T, Liu J and Fan D: Prognostic significance of osteopontin in hepatitis B virus-related hepatocellular carcinoma. Dig Liver Dis 39: 167-172, 2006.
58. Shevde LA, Samant RS, Paik JC, Metge BJ, Chambers AF, Casey G, Frost AR and Welch DR: Osteopontin knockdown suppresses tumorigenicity of human metastatic breast carcinoma, MDA-MB-435. Clin Exp Metastasis 23: 123-133, 2006.
59. Lin EY, Gouon-Evans V, Nguyen AV and Pollard JW: The macrophage growth factor CSF-1 in mammary gland development and tumor progression. J Mammary Gland Biol Neoplasia 7: 147-162, 2002.
60. Kacinski BM, Scata KA, Carter D, Yee LD, Sapi E, King BL, Chambers SK, Jones MA, Pirro MH, Stanley ER et al: FMS (CSF-1 receptor) and CSF-1 transcripts and protein are expressed by human breast carcinomas in vivo and in vitro. Oncogene 6: 941-952, 1991.
61. Scholl SM, Pallud C, Beuvon F, Hacene K, Stanley ER, Rohrschneider L, Tang R, Pouillart P and Lidereau R: Anti-colony-stimulating factor-1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis. J Natl Cancer Inst 86: 120-126, 1994.
62. McDermott RS, Deneux L, Mosseri V, Vedrenne J, Clough K, Fourquet A, Rodriguez J, Cosset JM, Sastre X, Beuzeboc P, Pouillart P and Scholl SM: Circulating macrophage colony stimulating factor as a marker of tumour progression. Eur Cytokine Netw 13: 121-127, 2002.
63. Toy EP, Chambers JT, Kacinski BM, Flick MB and Chambers SK: The activated macrophage colony-stimulating factor (CSF-1) receptor as a predictor of poor outcome in advanced epithelial ovarian carcinoma. Gynecol Oncol 80: 194-200, 2001.
64. Chambers SK, Kacinski BM, Ivins CM and Carcangiu ML: Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1. Clin Cancer Res 3: 999-1007, 1997.
65. Marks SC Jr and Lane PW: Osteopetrosis, a new recessive skeletal mutation on chromosome 12 of the mouse. J Hered 67: 11-18, 1976.
66. Wiktor-Jedrzejczak W, Bartocci A, Ferrante AW Jr, Ahmed-Ansari A, Sell KW, Pollard JW and Stanley ER: Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse. Proc Natl Acad Sci USA 87: 4828-4832, 1990.
67. Lin EY, Nguyen AV, Russell RG and Pollard JW: Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 193: 727-740, 2001.
68. Wyckoff J, Wang W, Lin EY, Wang Y, Pixley F, Stanley ER, Graf T, Pollard JW, Segall J and Condeelis J: A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res 64: 7022-7029, 2004.
69. Aharinejad S, Paulus P, Sioud M, Hofmann M, Zins K, Schafer R, Stanley ER and Abraham D: Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice. Cancer Res 64: 5378-5384, 2004.
70. Okazaki T, Ebihara S, Takahashi H, Asada M, Kanda A and Sasaki H: Macrophage colony-stimulating factor induces vascular endothelial growth factor production in skeletal muscle and promotes tumor angiogenesis. J Immunol 174: 7531-7538, 2005.
71. Tsutsumi H, Tanaka T, Ohashi N, Masuno H, Tamamura H, Hiramatsu K, Araki T, Ueda S, Oishi S and Fujii N: The therapeutic potential of the chemokine receptor CXCR4 antagonists as multi-functional agents. Biopolymers, 2006 [Epub ahead of print; DOI: 10.1002/bip. 20653].
72. Tamamura H, Tsutsumi H and Fujii N: The chemokine receptor CXCR4 as a therapeutic target for several diseases. Mini Rev Med Chem 6: 989-995, 2006.
73. Lee CH, Kakinuma T, Wang J, Zhang H, Palmer DC, Restifo NP and Hwang ST: Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases. Mol Cancer Ther 5: 2592-2599, 2006.
74. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E and Zlotnik A: Involvement of chemokine receptors in breast cancer metastasis. Nature 410: 50-56, 2001.
75. Pan J, Mestas J, Burdick MD, Phillips RJ, Thomas GV, Reckamp K, Belperio JA and Strieter RM: Stromal derived factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasis. Mol Cancer 5: 56, 2006.
76. Schimanski CC, Bahre R, Gockel I, Muller A, Frerichs K, Horner V, Teufel A, Simiantonaki N, Biesterfeld S, Wehler T, Schuler M, Achenbach T, Junginger T, Galle PR and Moehler M: Dissemination of hepatocellular carcinoma is mediated via chemokine receptor CXCR4. Br J Cancer 95: 210-217, 2006.
77. Sun YX, Schneider A, Jung Y, Wang J, Dai J, Wang J, Cook K, Osman NI, Koh-Paige AJ, Shim H, Pienta KJ, Keller ET, McCauley LK and Taichman RS: Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Miner Res 20: 318-329, 2005.
78. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL and Weinberg RA: Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121: 335-348, 2005.
79. Ohira S, Sasaki M, Harada K, Sato Y, Zen Y, Isse K, Kozaka K, Ishikawa A, Oda K, Nimura Y and Nakanuma Y: Possible regulation of migration of intrahepatic cholangiocarcinoma cells by interaction of CXCR4 expressed in carcinoma cells with tumor necrosis factor-alpha and stromal-derived factor-1 released in stroma. Am J Pathol 168: 1155-1168, 2006.
80. Yasumoto K, Koizumi K, Kawashima A, Saitoh Y, Arita Y, Shinohara K, Minami T, Nakayama T, Sakurai H, Takahashi Y, Yoshie O and Saiki I: Role of the CXCL12/CXCR4 axis in peritoneal carcinomatosis of gastric cancer. Cancer Res 66: 2181-2187, 2006.
81. Koishi K, Yoshikawa R, Tsujimura T, Hashimoto-Tamaoki T, Kojima S, Yanagi H, Yamamura T and Fujiwara Y: Persistent CXCR4 expression after preoperative chemoradiotherapy predicts early recurrence and poor prognosis in esophageal cancer. World J Gastroenterol 12: 7585-7590, 2006.
82. Ishikawa T, Nakashiro K, Hara S, Klosek SK, Li C, Shintani S and Hamakawa H: CXCR4 expression is associated with lymph-node metastasis of oral squamous cell carcinoma. Int J Oncol 28: 61-66, 2006.
83. Wehler T, Wolfert F, Schimanski CC, Gockel I, Herr W, Biesterfeld S, Seifert JK, Adwan H, Berger MR, Junginger T, Galle PR and Moehler M: Strong expression of chemokine receptor CXCR4 by pancreatic cancer correlates with advanced disease. Oncol Rep 16: 1159-1164, 2006.
84. Su L, Zhang J, Xu H, Wang Y, Chu Y, Liu R and Xiong S: Differential expression of CXCR4 is associated with the metastatic potential of human non-small cell lung cancer cells. Clin Cancer Res 11: 8273-8280, 2005.
85. Kim J, Mori T, Chen SL, Amersi FF, Martinez SR, Kuo C, Turner RR, Ye X, Bilchik AJ, Morton DL and Hoon DS: Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome. Ann Surg 244: 113-120, 2006.
86. Schimanski CC, Schwald S, Simiantonaki N, Jayasinghe C, Gonner U, Wilsberg V, Junginger T, Berger MR, Galle PR and Moehler M: Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer. Clin Cancer Res 11: 1743-1750, 2005.
87. Andre F, Cabioglu N, Assi H, Sabourin JC, Delaloge S, Sahin A, Broglio K, Spano JP, Combadiere C, Bucana C, Soria JC and Cristofanilli M: Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. Ann Oncol 17: 945-951, 2006.
88. Salvucci O, Bouchard A, Baccarelli A, Deschenes J, Sauter G, Simon R, Bianchi R and Basik M: The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study. Breast Cancer Res Treat 97: 275-283, 2006.
89. Kang H, Watkins G, Douglas-Jones A, Mansel RE and Jiang WG: The elevated level of CXCR4 is correlated with nodal metastasis of human breast cancer. Breast 14: 360-367, 2005.
90. Ottaiano A, Franco R, Aiello Talamanca A, Liguori G, Tatangelo F, Delrio P, Nasti G, Barletta E, Facchini G, Daniele B, Di Blasi A, Napolitano M, Ierano C, Calemma R, Leonardi E, Albino V, De Angelis V, Falanga M, Boccia V, Capuozzo M, Parisi V, Botti G, Castello G, Vincenzo Iaffaioli R and Scala S: Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients. Clin Cancer Res 12: 2795-2803, 2006.
91. Hansen LK, Wilhelm J and Fassett JT: Regulation of hepatocyte cell cycle progression and differentiation by type I collagen structure. Curr Top Dev Biol 72: 205-236, 2006.
92. White DJ, Puranen S, Johnson MS and Heino J: The collagen receptor subfamily of the integrins. Int J Biochem Cell Biol 36: 1405-1410, 2004.
93. Vogel WF, Abdulhussein R and Ford CE: Sensing extracellular matrix: an update on discoidin domain receptor function. Cell Signal 18: 1108-1116, 2006.
94. Ingber DE: Cellular mechanotransduction: putting all the pieces together again. FASEB J 20: 811-827, 2006.
95. Paszek MJ, Zahir N, Johnson KR, Lakins JN, Rozenberg GI, Gefen A, Reinhart-King CA, Margulies SS, Dembo M, Boettiger D, Hammer DA and Weaver VM: Tensional homeostasis and the malignant phenotype. Cancer Cell 8: 241-254, 2005.
96. Hall CL, Dai J, van Golen KL, Keller ET and Long MW: Type I Collagen Receptor ({alpha}2{beta}1) Signaling Promotes the Growth of Human Prostate Cancer Cells within the Bone. Cancer Res 66: 8648-8654, 2006.
97. Menke A and Adler G: TGFbeta-induced fibrogenesis of the pancreas. Int J Gastrointest Cancer 31: 41-46, 2002.
98. Koenig A, Mueller C, Hasel C, Adler G and Menke A: Collagen type I induces disruption of E-cadherin-mediated cell-cell contacts and promotes proliferation of pancreatic carcinoma cells. Cancer Res 66: 4662-4671, 2006.
99. Armstrong T, Packham G, Murphy LB, Bateman AC, Conti JA, Fine DR, Johnson CD, Benyon RC and Iredale JP: Type I collagen promotes the malignant phenotype of pancreatic ductal adenocarcinoma. Clin Cancer Res 10: 7427-7437, 2004.
100. Shintani Y, Hollingsworth MA, Wheelock MJ and Johnson KR: Collagen I promotes metastasis in pancreatic cancer by activating c-Jun NH(2)-terminal kinase 1 and up-regulating N-cadherin expression. Cancer Res 66: 11745-11753, 2006.
101. Pines M and Nagler A: Halofuginone: a novel antifibrotic therapy. Gen Pharmacol 30: 445-450, 1998.
102. Elkin M, Miao HQ, Nagler A, Aingorn E, Reich R, Hemo I, Dou HL, Pines M and Vlodavsky I: Halofuginone: a potent inhibitor of critical steps in angiogenesis progression. FASEB J 14: 2477-2485, 2000.
103. Elkin M, Reich R, Nagler A, Aingorn E, Pines M, de-Groot N, Hochberg A and Vlodavsky I: Inhibition of matrix metalloproteinase-2 expression and bladder carcinoma metastasis by halofuginone. Clin Cancer Res 5: 1982-1988, 1999.
104. Taras D, Blanc JF, Rullier A, Dugot-Senant N, Laurendeau I, Bieche I, Pines M and Rosenbaum J: Halofuginone suppresses the lung metastasis of chemically induced hepatocellular carcinoma in rats through MMP inhibition. Neoplasia 8: 312-318, 2006.
105. Abramovitch R, Dafni H, Neeman M, Nagler A and Pines M: Inhibition of neovascularization and tumor growth, and facilitation of wound repair, by halofuginone, an inhibitor of collagen type I synthesis. Neoplasia 1: 321-329, 1999.
106. Nagler A, Ohana M, Shibolet O, Shapira MY, Alper R, Vlodavsky I, Pines M and Ilan Y: Suppression of hepatocellular carcinoma growth in mice by the alkaloid coccidiostat halofuginone. Eur J Cancer 40: 1397-1403, 2004.
107. Abramovitch R, Itzik A, Harel H, Nagler A, Vlodavsky I and Siegal T: Halofuginone inhibits angiogenesis and growth in implanted metastatic rat brain tumor model - an MRI study. Neoplasia 6: 480-489, 2004.
108. de Jonge MJ, Dumez H, Verweij J, Yarkoni S, Snyder D, Lacombe D, Marreaud S, Yamaguchi T, Punt CJ and van Oosterom A: Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumours. Eur J Cancer 42: 1768-1774, 2006.